MedTrace Logo

Perioperative Insulin Glargine Dosing Study

NCT00309465 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 402

Last updated 2012-12-03

Study results available
· View outcomes & findings →

Summary

The main objective of this study is to compare three strategies of evening insulin glargine dosing to preoperative glucose values in patients with diabetes undergoing surgery to determine which dosing strategies most often achieves the admission target study values of 100-179 mg/dl.

Conditions

Interventions

DRUG

Lantus

Patients in Group 1 will administer 80% of their usual insulin glargine dose.

OTHER

Insulin

Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose

DRUG

Lantus

Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Tamra Dukatz

    lead OTHER

Principal Investigators

  • Tamra Dukatz, MSN, CRNA · William Beaumont Hospitals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2008-10-31
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00309465 on ClinicalTrials.gov